Abstract

PurposeWe combined conventional clinical and pathological characteristics and pathological architectural grading scores to develop a prognostic model to identify a specific group of patients with stage I lung adenocarcinomas with poor survival following surgery.MethodsThis retrospective study included 198 patients with stage I lung adenocarcinomas recruited from 2004 to 2013. Multivariate analyses were used to confirm independent risk factors, which were checked for internal validity using the bootstrapping method. The prognostic scores, derived from β-coefficients using the Cox regression model, classified patients into high- and low-risk groups. The predictive performance and discriminative ability of the model were assessed by the area under the receiver operating characteristic curve (AUC), concordance index (C-index) and Kaplan–Meier survival analyses.ResultsThree risk factors were identified: T2 (rounding of β-coefficients = 81), necrosis (rounding of β-coefficients = 67), and pathological architectural score of 5–6 (rounding of β-coefficients = 58). The final prognostic score was the sum of points. The derived prognostic scores stratified patients into low- (score ≤ 103) and high- (score > 103) risk groups, with significant differences in 5-year overall survival (high vs. low risk: 49.3% vs. 88.0%, respectively; hazard ratio: 4.55; p < 0.001). The AUC for the proposed model was 0.717. The C-index of the model was 0.693.ConclusionAn integrated prognostic model was developed to discriminate resected stage I adenocarcinoma patients into low- and high-risk groups, which will help clinicians select individual treatment strategies.

Highlights

  • Lung cancer is the leading cause of cancer death in males and the second leading cause of cancer death in females worldwide (Torre et al 2016)

  • Patients with early-stage non-small-cell lung cancers (NSCLCs) after complete surgical resection are at substantial risk for recurrence

  • The role of adjuvant chemotherapy for stage I patients is still controversial because previous randomized trials have not reported consistent results (Kris et al 2017; Bradbury et al 2017)

Read more

Summary

Introduction

Lung cancer is the leading cause of cancer death in males and the second leading cause of cancer death in females worldwide (Torre et al 2016). The 5-year survivals of patients with pathological stage IA after surgery are 92%, 86%, and 81% for stages IA1, IA2, and IA3, respectively (Nowak et al 2016). Journal of Cancer Research and Clinical Oncology (2020) 146:801–807. According to the American Society of Clinical Oncology adjuvant therapy guideline for resected non-small-cell lung cancers (NSCLCs), adjuvant chemotherapy is recommended for patients with stage IIA, IIB, or IIIA disease who have undergone complete surgical resection (Kris et al 2017). The indications for postoperative chemotherapy for stage I patients are still controversial (Bradbury et al 2017). The decision of which stage IB patients to treat with adjuvant chemotherapy is not as clear as in other stages. Additional prognostic markers beyond stage are needed to determine who may be in need of adjuvant chemotherapy or more aggressive treatment approach

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call